HLN · Pharma and healthcare · one day
Haleon (HLN): news on Wednesday 28 October 2026
News from the 24 hours to Wednesday morning, 28 October 2026.
Tone of the day
What the score means. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.
Why it scored this way
Coverage was mostly previews of Haleon's upcoming quarterly trading update, with Goldman Sachs keeping a Buy rating. Caution about slower volumes and reliance on the cold season tempers the mildly positive tone.
What drove it
- Q3 results preview
- analyst rating
- volume slowdown
Around this day
| Day | Tone | Headlines |
|---|---|---|
| Thu 22 Oct | +6.0 | 2 |
| Fri 23 Oct | +3.7 | 6 |
| Sat 24 Oct | +2.3 | 5 |
| Sun 25 Oct | +5.7 | 3 |
| Mon 26 Oct | −1.2 | 3 |
| Tue 27 Oct | +4.2 | 2 |
| Wed 28 Oct | +1.3 | 5 |
2 stories · 5 headlines · strongest first
Pharma and healthcare on 28 OctoberFTSE 100 that day| Tone | What the article reported, and why it scored that way | |
|---|---|---|
| Haleon Q3 trading update previews −0.44 headlines today · Previews say Haleon will report organic growth figures, and UBS points to higher prices alongside softer volumes. | ||
| −2.0 | Outlook for next year's guidance seen as dependent on seasonal illness levels. | |
| +0.8 | Broker expects pricing gains offset by weaker volumes ahead of quarterly update. | |
| −0.8 | Shares watched ahead of sector updates, with some uncertainty. | |
| +0.5 | Preview of upcoming trading update, focused on underlying growth. | |
| Goldman Sachs reiterates Buy on Haleon at 460p +7.01 headline today · Goldman Sachs keeps its Buy rating and 460p target. | ||
| +7.0 | Broker keeps positive rating with a price target above current levels. | |
Each article has its own score. The lines are our own summary; follow the source link to read the article itself.
Follow by email
A short, free morning email on how the news treated Haleon: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.